¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Test, prostate specific antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® scratch test ÇÑ±Û ³­Àý¹ý
¼³¸í   
  ÇǺθ¦ ³¯Ä«·Î¿î ¹Ù´Ã·Î ±Ü¾î ÇǺÎÀÇ ¹ÝÀÀÀ» º¸´Â °Ë»ç·Î ÇǺΠ°ú¹Î¹ÝÀÀÀ̳ª ¾Ë·¹¸£±â¸¦ ¾Ë¾Æº¸±â À§ÇÑ °Ë»çÀÌ´Ù. ¹Ù´Ã³¡¿¡ Ç׿øÀ» ¹¯Èù µÚ, ÇǺιØÀ» ±Ü¾î ¹ÝÀÀÀ» ¾Ë¾Æº»´Ù. À̶§ Ç׿øÀÌ ¾Æ´Ñ ´ëÁ¶¹°Áú(¿¹¸¦ µé¾î º¸ÅëÀÇ ¹°)À» ¹¯Èù ¹Ù´ÃÀ» °°ÀÌ ¹ÝÀÀÇÏ¿© ÇǺ馱âÁõ(dermographism) ´ÜÁö ¹Ù´ÃÀÇ ±ÜÈû¸¸À¸·Î ¾Ë·¹¸£±â °°Àº ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Çö»ó°ú °¨º°ÇؾߠÇÑ´Ù.
  
  ³­Ã», Ã»·Â¼Ò½Ç(hearing loss)
  
  Ã»°¢ÀÌ ÀúÇÏ ¶Ç´Â »ó½ÇµÈ »óÅÂ. ¿øÀΰú Á¤µµ´Â ¿©·¯ °¡ÁöÀε¥, ³­Ã»Àº ±× Á¤µµ°¡ °¡Àå ½ÉÇÑ »óÅÂÀÌ´Ù. Ã»°¢ÀÇ Àüµµ°æ·Î¿¡ Àå¾Ö°¡ ÀÖÀ» ¶§ ³­Ã»ÀÌ ÀϾ°í, ±× º´ÅͰ¡ ¿ÜÀ̵µ³ª ÁßÀÌ¿¡ Àִ °ÍÀ» ÀüÀ½³­Ã», ³»ÀÌ¿¡ Àִ °ÍÀ» °¨À½ ³­Ã»À̶ó ÇÏ¿© ±¸ºÐÇÑ´Ù. ¶Ç º´ÅÍÀÇ ÀÚ¸®¸¦ ¸í½ÃÇÏ¿© ÁßÀ̼º ³­Ã»À̳ª ¹Ì·Î¼º ³­Ã» µîÀ¸·Î ¼¼ºÐÇϱ⵵ ÇÑ´Ù.
¿µ¹® stool guaiac test ÇÑ±Û ´ëº¯ ±¸¾ÆÀÌ¾Ç °Ë»ç
¼³¸í   
  ´ëº¯³»¿¡ ÀÖÀ» ¼ö Àִ ÀáÇ÷(´«¿¡ º¸ÀÌÁö ¾Ê´Â ÃâÇ÷)À¯¹«¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î, Ç÷±¸³»ÀÇ heme peroxidase¿¡ ÀÇÇØ guaiacÀÌ »êÈ­µÇ´Â ¹ÝÀÀÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÑ´Ù. ¹æ¹ýÀº 3Àϰ£¿¡ °ÉÃÄ ÇÑ º¯¿¡¼­ 2±ºµ¥¾¿ Ã¤ÃëÇÏ¿© °Ë»çÇÑ´Ù. À§¾ç¼º ¹ÝÀÀ(°ÅÁþÀ¸·Î Ç÷¾×ÀÌ ÀÖ´Ù°í ³ªÅ¸³ª´Â ¹ÝÀÀ)Àº ½Ä¹° °ú»êÈ­È¿¼Ò¸¦ ÇÔÀ¯Çϰí Àִ ȫ´ç¹«ÀÇ ¼·Ã볪 Ç÷±¸ ¼ººÐÀ» ÇÔÀ¯Çϰí Àִ °í±â ¼·Ã렵¼­ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, À§À½¼º ¹ÝÀÀ(½ÇÁ¦·Î Ç÷¾×Àº ÀÖÁö¸¸, Ç÷¾×ÀÌ ¾ø´Ù°í ³ªÅ¸³ª´Â ¹ÝÀÀ)Àº È¯¿ø·ÂÀ» °¡Áö°í Àִ ºñŸ¹Î CÀÇ º¹¿ë½Ã ³ªÅ¸³¯ ¼ö ÀÖ´Ù. Æ¯È÷ À§¾ç¼º ¹ÝÀÀÀÌ ¸Å¿ì ÈçÇÏ´Ù.
¿µ¹® Rorschach Test ÇÑ±Û ·Î¸£»þÇÏ °Ë»ç
¼³¸í   
  »ç°íÀå¾Ö¿Í Á¤¼­Àå¾Ö¿¡ ¹Î°¨ÇÑ Åõ»ç°Ë»ç(projective test). °ËÀº»ö°ú ¸î°¡Áö »öÀ¸·Î ÀÌ·ç¾îÁø À×Å©¾ó·è°°Àº µµÇüÀÌ ±×·ÁÁø 10°³ÀÇ Ä«µå¸¦ ÀÌ¿ëÇÑ´Ù. ÇǰËÀÚ¿¡°Ô Ä«µå¸¦ º¸ÀÌ°í º» °Í¿¡ ´ëÇØ ¸»Çϵµ·Ï ÇÑ´Ù. ´ÙÀ½¿¡´Â ¾ó·èÀÇ ¾î´À À§Ä¡°¡ ÇǰËÀÚ°¡ ¸»ÇÑ Áö°¢´ë»óÀ» ¾Ï½ÃÇÏ´ÂÁö Ã£µµ·Ï ÇÑ´Ù. ÇǰËÀÚÀÇ ´äº¯À» ºÐ¼®Çϸ頱×ÀÇ »ç°í¿Í Á¤¼­»óÅ¿¡ ´ëÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ´Ù. 
¿µ¹® Mantoux test ÇÑ±Û ¸ÁÅä¿ì°Ë»ç
¼³¸í   
  ¼Ò¾Æ¿¡ ÁַΠ½Ç½ÃÇϴ °Ë»ç ¹æ¹ýÀ¸·Î, BCGÁ¢Á¾ÈÄ¿¡³ª È¤Àº °áÇÙ±Õ¿¡ ÇѹøÀ̶󵵠³ëÃâµÈ °æ¿ì¿¡ ¾ç¼º¹ÝÀÀÀ¸·Î ³ª¿Â´Ù. ¿ì¸®³ª¶ó¿¡¼­´Â »ýÈÄ 1°³¿ù¿¡ BCG¿¹¹æÁ¢Á¾À» ½ÃÇàÇϹǷΠ´ëºÎºÐ ¾ç¼ºÀ¸·Î ³ª¿À°Ô µÇ³ª, ÀÌ ¿¹¹æÁ¢Á¾À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼­ ¾ç¼ºÀ¸·Î ³ª¿À¸é, °áÇÙ±ÕÀǠħÅõ¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Ù.
¿µ¹® stress test ÇÑ±Û ½ºÆ®·¹½º °Ë»ç
¼³¸í   
  Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î È¯ÀÚ¿¡°Ô¼­ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼­ È¯ÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼­ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù.
  
  ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼­µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³­´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • donor-specific phage
    Á¦°øÀÚÆ¯ÀÌÆÄÁö, °ø¿©ÀÚÆ¯ÀÌÆÄÁö
  • group-specific
    ±ºÆ¯ÀÌ-
  • neuron-specific enolase
    ´º·±Æ¯ÀÌ¿¡³î¶ó¾ÆÁ¦
  • species-specific
    Á¾Æ¯ÀÌ-
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • specific
    1. ƯÀÌ-, ƯÁ¤- 2. Á¾-
  • specific absorption rate
    ºñÈí¼öÀ²
  • specific action
    ƯÀÌÀÛ¿ë
  • specific activity
    1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific capsular reaction
    ƯÀÌÇǸ·¹ÝÀÀ
  • specific charge
    ºñÀüÇÏ, °ßÁÜÀüÇÏ
  • specific compliance
    ºñ¼øÀÀµµ
  • specific conductivity
    ºñÀüµµÀ²
  • specific death rate
    ƯÀÌ»ç¸Á·ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen presentation
    Ç׿øÀü´Þ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • nitroblue tetrazolium test
    ´ÏÆ®·Îºí·çÅׯ®¶óÁ¹·ý°Ë»ç
  • test strip
    °Ë»ç¶ì
  • test
    °Ë»ç, ½ÃÇè
  • absorption test
    Èí¼ö½ÃÇè, Èí¼ö°Ë»ç
  • agglutination test
    ÀÀÁý°Ë»ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • anticholinesterase test
    Ç×Äݸ°¿¡½ºÅ×¶óÁ¦°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • blood test
    Ç÷¾×°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • specific pathogen free animal
    ƯÁ¤¹«º´¿øÃ¼µ¿¹°
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • cause-specific rate
    ¿øÀκ°Æ¯¼öÀ²
  • specific charge
    °ßÁÜÀüÇÏ, ºñÀüÇÏ
  • specific compliance
    ƯÀÌź¼º, ƯÀÌÀ¯¼øµµ, ƯÀÌÀÀ¶ô
  • specific conductivity
    ºñÀüµµÀ²
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • donor-specific phage
    Á¦°øÃ¼Æ¯ÀÌÆÄÁö, ÁÖ°ÔÆ¯ÀÌÆÄÁö
  • specific disease
    ƯÀÌÁúȯ
  • specific reading disability
    ƯÁ¤ÀбâÀå¾Ö
  • group-specific
    ±ºÆ¯ÀÌ-
  • specific granule
    ƯÀ̰ú¸³
  • specific gravity
    ºñÁß
  • specific heat
    ƯÀÌ¿­
  • specific humidity
    ºñ½Àµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prostate
    Àü¸³¼±
  • prostate
    Àü¸³¼±(îñí¡àÍ)
  • prostate capsule
    Àü¸³¼±ÇǸ·
  • prostate carcinoma
    Àü¸³¼±¾ÏÁ¾(îñí¡àÍäßðþ)
  • prostate gland
    Àü¸³»ù, Àü¸³¼±(îñí¡àÍ).
  • prostate gland
    Àü¸³¼±
  • prostate utricle
    Àü¸³¼±¼Ò½Ç
  • SDA= specific dynamic action
    ƯÀ̵¿Àû ÀÛ¿ë.
  • age specific death rate
    ¿¬·Éº° »ç¸Á·ü
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group-specific
    ±ºÆ¯ÀÌÀÇ
  • group-specific C carbohydrate
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immunity, specific
    ƯÀ̸鿪
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • species specific antigen
    Á¾Æ¯ÀÌÇ׿ø(ðú÷åì¶ù÷ê«).
  • specific antigen, organ
    Àå±âƯÀÌÇ׿ø
  • tissue specific antigen
    Á¶Á÷ƯÀÌÇ׿ø(¡­÷åì¶ù÷ê«).
  • tumor specific antigen
    Á¾¾çƯÀÌ(¼º)Ç׿ø(ðþåË÷åì¶àõù÷ê«).
  • tumor specific antigen
    Á¾¾çƯÀÌÇ׿ø
  • tumor specific antigen
    Á¾¾çƯÀÌ(¼º)Ç׿ø(ðþåË÷åì¶àõù÷ê«)
  • tumor specific transplantation antigen
    Á¾¾çƯÀÌÀ̽ÄÇ׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«).
  • tumor specific transplantation antigen
    Á¾¾çƯÀÌÀ̽ÄÇ׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • tumor-specific antigen
    Á¾¾çƯÀÌÇ׿ø(ðþåË÷åì¶ù÷ê«)
  • type specific antigen
    ÇüƯÀÌÇ׿ø
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½ºÆ¯ÀÌ (¼º)Ç¥¸éÇ׿ø
  • capsular antigen =K. antigen
    Çù¸·Ç׿ø(¡­ù÷ê«).
  • specific gravity test
    ºñÁß½ÃÇè(ÝïñìãËúÐ).
  • abscess of prostate
    Àü¸³¼± ³ó¾ç
  • apex of prostate
    Àü¸³»ù²ÀÁö
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • screening test
    ¼±º°°Ë»ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • specific dynamic action
    ƯÀÌ µ¿Àû ÀÛ¿ë(÷åì¶ÔÑîÜíÂéÄ)
  • specific extinction coefficient
    ºñÈí±¤ °è¼ö(ÝïýåÎÃÌõâ¦)
  • specific gravity
    ºñÁß(Ýïñì)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • specific heat
    ºñ¿­(Ýïæð)
  • specific immune suppression
    ƯÀÌ ¸é¿ª¾ï¾Ð(÷åì¶Øóæ¹åääâ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • specific interaction theory
    ƯÀÌ »óÈ£ÀÛ¿ëÀÌ·Ð(÷åì¶ßÓû»íÂéÄ×âÖå)
  • specific ionization
    ºñ(Ýï) ÀÌ¿ÂÈ­(ûù)
  • specific radioactivity
    ºñ¹æ»ç´É(ÝïÛ¯ÞÒÒö)
  • specific rate constant
    ƯÀÌ ¼Óµµ»ó¼ö(÷åì¶áÜÓøßÈâ¦)
  • specific reaction rate
    ƯÀÌ ¹ÝÀÀ¼Óµµ(÷åì¶ÚãëëáÜÓø)
  • specific refractive index increment
    ƯÀÌ ±¼ÀýÁö¼ö Áõ°¡(÷åì¶ÏÝï¹ò¦â¦ñòÊ¥)
  • specific retention volume
    ºñ Àú·ù ¿ëÀû(ÝïîÍ×µé»îÝ)
  • specific rotation
    ºñ¼±±¤µµ(ÝïàÁÎÃÓø)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dye dilution test
    »ö¼ÒÈñ¼®½ÃÇè
  • guaiac test
    °úÀ̾׽ÃÇè
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • laboratory test
    °Ë»ç
  • pivot shift test
    ÃßÃà º¯À§½ÃÇè
  • provocation test
    À¯¹ß½ÃÇè
  • provocative test
    À¯¹ß½ÃÇè
  • pulmonary function test
    Æó±â´É°Ë»ç
  • qualitative test
    Á¤¼º½ÃÇè
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • routine test
    »ó¿ë Å×½ºÆ®
  • screening test
    ¼±º°°Ë»ç, ¿¹ºñ°Ë»ç
  • serologic test
    Ç÷û(ÇÐÀû)°Ë»ç
  • sigle blind test
    ´ÜÀϸͽÃÇè
  • skin test
    ÇǺÎ(¹ÝÀÀ)°Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PSAD prostate-specific antigen density
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
PAT Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili...
HLA histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod...
ACPP adrenocortical polypeptide; prostate-specific acid phosphatase
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FPSA free prostate specific antigen
TPSA total prostate specific antigen
PAP Prostate specific acid phosphatase
PSAP prostate specific acid phosphatase
PSCA Prostate Stem Cell Antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific congenital heart defects
    °³º° º´¼Ò
  • specific criteria
    ƯÀÌÇÑ ±âÁØ
  • specific dentist-patient relationship
    µ¶Æ¯ÇÑ Ä¡°ú ÀÇ»ç-ȯÀÚ °ü°è
  • specific energy of sense
    Ư¼ö °¨°¢ ¿¡³ÊÁö
  • specific gamma emission
    Ư¼ö °¨¸¶ ¹æÃâ
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • specific inflammation
    ƯÀ̼º ¿°Áõ
  • specific membrane receptor
    ƯÁ¤ ¸· ¼ö¿ë±â
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific receptor
    ƯÀÌ ¼ö¿ëü, ƯÀÌ ¼ö¿ë±â
  • specific region
    ƯÀÌ ºÎÀ§
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • specific weight
    ºñÁß
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
  • accessible antigen
    Á¢±Ù °¡´É Ç׿ø, ±ÙÁ¢ Ç׿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
posterior surface of prostate The posterior surface of the prostate.
Synonym: facies posterior prostatae.
(05 Mar 2000)
prostate A small conical gland at the base of the male bladder and surrounding the first part of the urethra.
(27 Sep 1997)
prostate acid phosphatase An enzyme produced by the prostate that is elevated in some patients with prostate cancer.
(12 Dec 1998)
prostate anatomy <radiology> Periurethral glandular tissue, may lead to BPH, prostatic acinar tissue, central zone may lead to BPH, peripheral zone may lead to carcinoma
(12 Dec 1998)
prostate cancer The second most common malignancy in men. A malignant tumour of glandular origin in the prostate. Over 95% are adenocarcinomas. Most commonly seen in older men, with the age of 73 being the average age at the time of diagnosis. A family history for prostate cancer and perhaps, a diet that is high is fat are considered to be risk factors for this malignancy. Early detection is possible through annual digital rectal examinations and routine PSA testing.
(27 Sep 1997)
prostate carcinoma <radiology> Treatment: stages A and B: radical prostatectomy (prostate, seminal vesicles, part of bladder); some do simple prostatectomy for stage A, stage C: radiation therapy, stage D: orchiectomy and/or oestrogens
stage A Tumour discovered incidentally in tissue removed for BPH, A1 Small focal involvement of one lobe, A2 Multifocal or diffuse carcinoma, Stage B Palpable carcinoma confined to prostate on digital exam, B1 Solitary nodule less than 1.5 cm, B2 Diffuse involvement of both lobes, Stage C Tumour extending through the prostate capsule; no metastasis, Stage D Metastases, usually to bone and/or pelvic lymph nodes
(12 Dec 1998)
prostate gland A gland in the male that surrounds the neck of the bladder and urethra. The prostate contributes to the seminal fluid.
(16 Dec 1997)
nodular hyperplasia of prostate Glandular and stromal hyperplasia occurring very commonly in the middle and lateral lobes of older men, forming nodules that may increasingly obstruct the urethra.
Synonym: benign prostatic hypertrophy.
(05 Mar 2000)
inferolateral surface of prostate The surface of the prostate facing the body of the pubis and the pelvic diaphragm.
Synonym: facies inferolateralis prostatae.
(05 Mar 2000)
isthmus of prostate The narrow middle part of the prostate anterior to the urethra.
Synonym: isthmus prostatae.
(05 Mar 2000)
elevator muscle of prostate <anatomy> In the male, the most medial fibres of the levator ani (pubococcygeus) muscle that extend from the pubis into the fascia of the prostate.
Synonym: musculus levator prostatae, elevator muscle of prostate.
(05 Mar 2000)
fascia of prostate The condensation of pelvic visceral fascia that encloses the prostate gland.
Synonym: fascia prostatae.
(05 Mar 2000)
female prostate Term sometimes applied to the periurethral glands in the upper part of the urethra in the female.
(05 Mar 2000)
lobe of prostate One of the lateral lobes (right or left) or the middle lobe or isthmus of the prostate; in the adult the lobes are ill-defined.
Synonym: lobus prostatae.
(05 Mar 2000)
aspergillus antigen skin test <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Partial Test Ban Treaty
    ºÎºÐÀû ÇÙ½ÇÇè ±ÝÁö Á¶¾à
  • Rorschach test
    ·Î¸£»þÇÏ Å×½ºÆ®(À×Å©ÀÇ ¾ó·è°£Àº ¹«ÀǹÌÇÑ ¹«´Ì¸¦ ÇØ¼®½ÃÄÑ »ç¶÷ÀÇ ¼º°ÝµîÀ» ¾Ë¾Æ³»´Â °Ë»ç)
  • Wassermann test
    ¹Ù¼­¸¸ °Ë»ç(¹ÝÀÀ);¸Åµ¶ÀÇ Ç÷û Áø´Ü
  • achievement test
    Çз°˻ç
  • acid test
    »ê½ÃÇè;¾ö¹ÐÇѽÃÇè
  • alpha test
    Áö´ÉÅ×½ºÆ®
  • blood test
    Ç÷¾×°Ë»ç
  • breath test
    ÁÖ±â°Ë»ç
  • captive test (firing)
    (¹Ì»çÀÏ.·ÎÄÏ ¿£ÁøµîÀÇ)Áö»ó ºÐ»ç ½ÃÇè
  • cartoon test
    ¾àÈ­ Å×½ºÆ®
  • completion test
    ¿Ï¼ºÇü Å×½ºÆ®
  • doping test
    ±ÝÁö ¾à¹° °Ë»ç
  • doublebline test
    ÀÌÁß¸Í °Ë»ç¹ý(½Å¾à È¿°úÀÇ °Ë»ç¹ý)
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
  • drop test
    ³«ÇÏ ½ÃÇè(Å×½ºÆ®)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á